Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy

This study compared the incidence of febrile neutropenia from the use of granulocyte colony-stimulating factor filgrastim versus its biosimilar, filgrastim-sndz, in patients with nonmyeloid cancers receiving chemotherapy. The researchers also compared the resulting health care costs and resource utilization.

Journal of Managed Care & Specialty Pharmacy